A clinico-genetic study based on the Innsbruck MSA Registry
Objective: To assess family history (FH) for neurodegenerative disorders in people with multiple system atrophy (MSA), compare its prevalence with that of a prospectively recruited…Comorbid neuropathological features in multiple system atrophy
Objective: To elucidate the distribution of comorbid neuropathology in multiple system atrophy (MSA) and its clinical correlation. Background: Multiple protein accumulations are often present in…An Eye of a Tiger cannot see all the true: a case series.
Objective: Describe patients with Multiple System Atrophy with iron accumulation in neuroimaging of striatal regions. Background: MSA is an adult neurodegenerative disease with parkinsonism, cerebelar…Alteration of lysosomal enzymatic activities in patients with multiple system atrophy
Objective: To estimate whether alteration of lysosomal activities contributes to synucleinophaties pathogenesis. Background: Multiple system atrophy (MSA) belongs to a group of neurodegenerative disorders termed synucleinopathies, which also include Parkinson's disease (PD)…Plasma Short-Chain Fatty Acids Differences in Multiple System Atrophy from Parkinson’s Disease
Objective: We aimed to investigate the plasma short-chain fatty acids (SCFAs) in multiple system atrophy (MSA) patients and to identify the potential differential diagnostic ability.…Mapping regional alpha-synuclein seeding capacity in Multiple System Atrophy
Objective: The objective of our work was to develop a novel high-throughput cell-free assay that allowed us to perform a comprehensive characterization of α-synuclein seeding…The relationship between MIBG myocardial scintigraphy and clinical factors in multiple system atrophy
Objective: This study aimed to clarified the relationship between the degree of MIBG accumulation and clinical factors in patients with MSA. Background: 123I-MIBG myocardial scintigraphy considered to…Alpha-synuclein and Amyloid beta peptide 1-42 in Parkinson’s disease and parkinsonian plus syndrome cohorts
Objective: To evaluate the serum levels of α-synuclein (α-syn) and Amyloid β 1-42 (Aβ1-42) in the patients of Parkinson’s disease (PD), progressive supranuclear palsy (PSP)…Mass spectrometry-based proteomics brain analysis to distinguish between Parkinson syndromes
Objective: To address the gap existing during clinical diagnosis in differentiating among various forms of Parkinson syndrome (PS) by using mass spectrometry (MS)-based brain proteomics.…Detection of alpha-synuclein aggregation from submandibular and esophageal tissue of patients with synucleinopathies
Objective: Utilize cyclic amplification methods to facilitate detection of aggregation prone forms of a-syn from submandibular or esophageal tissue of patients with syncleinopathies. Background: In…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.